PRP Therapy For Anosmia Is Gaining Attention Fast
PRP therapy for anosmia is an emerging, office-based treatment that uses a patient's own concentrated platelets, injected into the upper nasal cavity, to try to improve smell loss when standard measures have not worked. Early studies suggest it may help some people with persistent anosmia, especially after COVID-19 or head injury, but it is still considered investigational rather than a proven standard treatment.
What PRP therapy is
Platelet-rich plasma is made by drawing a small amount of blood, spinning it to concentrate platelets, and injecting that plasma into targeted tissue. In smell-loss care, clinicians place PRP high in the nose near the olfactory clefts, where smell nerves and supporting cells are located, with the goal of reducing inflammation and encouraging tissue repair.
This approach is attractive because it uses the patient's own blood products and usually does not require surgery or general anesthesia. Most published protocols describe in-office injections and short follow-up intervals, which makes the treatment relatively simple from a procedural standpoint.
Why clinicians are interested
Interest in PRP has grown because anosmia can be stubborn, especially when it lasts for months after a viral illness, including COVID-19. Olfactory training and steroids are still common first-line options, but clinicians are looking for therapies that may help patients who remain symptomatic after those measures.
The most encouraging evidence so far comes from early clinical studies and controlled trials showing measurable improvements in smell testing and patient-reported quality of life. In one 2023 study, many patients improved after intranasal PRP, with no adverse outcomes reported, while a 2025 controlled longitudinal study found higher smell-test gains in PRP groups than controls.
Who it may help
PRP therapy is being studied most often for people with persistent smell loss that has lasted at least several months, particularly after COVID-19, another viral infection, or trauma. Some clinics also mention patients with parosmia or hyposmia, but the strongest real-world interest remains in chronic post-viral anosmia.
- Persistent smell loss lasting 6 months or longer.
- Post-viral anosmia, including after COVID-19.
- Smell loss after head injury or trauma.
- People who have not improved with smell training or standard medications.
What the evidence shows
Current evidence is promising but still incomplete. A 2023 PubMed-indexed study reported that patients experienced subjective improvement after intranasal PRP, with objective improvement seen at three months and no adverse outcomes from the injections.
In 2025, the American Academy of Otolaryngology-Head and Neck Surgery reported preliminary findings in post-traumatic smell loss showing that 67% of treated patients reported subjective improvement after a single injection, with measurable gains by three months. Another 2025 study in COVID-19-related smell loss found significantly greater improvements in smell scores in PRP groups than in controls, and quality-of-life gains were especially notable in patients with parosmia.
That said, the field is still early. Most studies are small, protocols vary, and researchers are still trying to determine the best dose, injection schedule, and patient selection criteria.
Typical treatment process
Most PRP programs for anosmia follow a short outpatient pathway. A clinician usually draws blood, prepares the plasma, and injects it into the upper nasal area near the olfactory clefts; some protocols use one injection, while others use a series spaced over weeks.
- Initial evaluation and smell-loss history.
- Blood draw and PRP preparation.
- Intranasal injection into the olfactory area.
- Follow-up visits for repeat testing and symptom tracking.
Some clinics report three injections about two weeks apart, while others use a different schedule that includes follow-up at around three months or additional sessions depending on response.
Benefits and limits
The main appeal of PRP is that it is minimally invasive, uses the patient's own blood, and has shown a favorable short-term safety profile in published studies. Reported side effects are usually mild, such as temporary soreness, pressure, or nasal irritation.
The main limitation is uncertainty. PRP is not yet a universally accepted standard of care for anosmia, and many patients will still need time, smell training, and management of underlying causes before any procedural treatment is considered.
| Feature | What current reports suggest | Source context |
|---|---|---|
| Delivery | In-office intranasal injection into the olfactory cleft | PRP smell-loss clinics and studies |
| Best-studied use | Persistent post-viral or post-COVID anosmia | Clinical reports and trials |
| Reported benefit | Some patients show meaningful smell-score and quality-of-life gains | 2023 and 2025 studies |
| Safety | Usually mild, temporary nasal side effects; serious events uncommon in published reports | Published study summaries |
| Status | Promising but still investigational | Expert and trial context |
"PRP appears safe for use in the treatment of olfactory loss, and preliminary data suggest possible efficacy, especially for those with persistent loss."
Risks and safety
Available reports suggest PRP is generally well tolerated, with no serious complications reported in some small studies and mostly mild local effects in clinic summaries. Because the product comes from the patient's own blood, the treatment avoids many concerns associated with foreign substances, but it still should be performed by a trained ENT or smell-disorders specialist.
People considering PRP should still discuss bleeding risk, nasal anatomy, medications, and the cause of the smell loss before proceeding. A careful workup matters because anosmia can also be related to chronic sinus disease, trauma, neurologic conditions, or other treatable problems.
What patients should expect
Patients usually want to know whether PRP restores smell completely, and the honest answer is that results vary. Some people report noticeable improvement within weeks, while others improve more gradually or not at all, and a subset may need repeat procedures or continued smell training.
For now, PRP is best understood as a promising option for selected patients with persistent anosmia who have already tried standard therapies. It is gaining attention because the early data are encouraging, but larger randomized trials are still needed before it can be considered routine care.
Key concerns and solutions for Prp Therapy For Anosmia Is Gaining Attention Fast
How effective is PRP for anosmia?
Early studies suggest PRP may improve smell function in some patients, with better outcomes reported in certain post-viral and post-traumatic cases, but effectiveness is not guaranteed and remains under active study.
Is PRP for smell loss safe?
Published reports so far describe mostly mild temporary side effects, and several studies reported no serious complications, though the evidence base is still relatively small.
Who is most likely to benefit?
Patients with persistent smell loss lasting months, especially after COVID-19, another viral infection, or head trauma, appear to be the main group being studied and treated by specialty clinics.
Is PRP a standard treatment?
No. PRP for anosmia is still considered emerging or investigational, which means it is promising but not yet supported by enough large, definitive trials to be called standard care.